SLC10A1 and cholestasis: Future studies should address if blood BA concentrations in cholestasis can be decreased even further by combining systemic ASBTi7,15 with additional drugs, such as synthetic FXR agonists, FGF15/19 mimetics or PPAR agonists to inhibit BA synthesis,[16], [17], [18], [19], [20] NTCP inhibitors to block hepatic BA uptake, or with therapeutic BAs to reduce lipophilicity of the BA pool.[21], [22], [23]